Biotech • Diagnostics • Medical Devices • Digital Health

Turn complex biology into durable patent rights.

Scientist‑led drafting and seasoned prosecution for founders, PIs, and R&D teams across therapeutics, diagnostics, tools, devices, and computational biology.

Book a 30‑minute consult Get a quote in 24 hours
Startups • University spin‑outs • Therapeutics • Diagnostics • Tools & reagents
Same‑day replyNo cost.
Clear budgetsFixed or capped fees available.
Portfolio‑first strategyFilings that serve the business.

Who we help

Biotech
Diagnostics
Medical Devices
Digital Health
Tools & Reagents

Scientist‑literate counsel that bridges the bench and the boardroom. We draft enabling specifications with commercialization in mind, then prosecute with a strategy that anticipates real‑world prior art and markets.

What you’ll get
  • Commercial‑ready specs
  • Strategic claim drafting
  • Transparent budgets and fees
Are we a fit?
  • Provisional & non‑provisional
  • US/EU portfolio planning
  • Patent and timing advice
How we work
  • 30‑minute consult: Conflicts check if needed
  • Plan & quote: Delivered within 24 hours
  • Draft & file: with milestone check‑ins
Past results do not guarantee similar outcomes.

Case snapshots

Diagnostics — workflow protection

Allowed claims covering the entire assay workflow — from sample preparation through detection — with robust method steps that navigated dense prior art. Our continuation application is pending on software‑assisted analysis that integrates instrument control and signal processing to ensure end‑to‑end protection across instruments and software.

Therapeutics — PCT → US allowance

Treatment methods were strategically narrowed to overcome prior art without sacrificing clinical endpoints, ensuring the claims retained commercial relevance. We also preserved future options for biologic formulations and combination claims in the portfolio plan to provide long‑term flexibility as the therapy advances.

Tools/Devices — data pipeline

We secured protection for both consumables and device–software integration across LIMS/ELN workflows, ensuring data integrity throughout the pipeline. Detailed figures were drafted to support apparatus and method claims, capturing how hardware and software interact to deliver end‑to‑end laboratory solutions.

Insights

Strategy

When to convert a fast provisional

How to triage data‑dependent claims vs. platform claims and keep your options open across U.S./EP timelines.

Devices

Drafting for device‑software integrations

Aligning claims with FDA/CE documentation so that IP supports regulatory and commercialization milestones.

Prosecution

Responding to Wands‑type enablement attacks

Using figures and experimental bands to demonstrate predictability without giving up breadth.

Ready to talk?

Same‑day response during business hours (Pacific Time).

  • No‑cost initial consult.
  • Initial inquiries are treated as confidential under California law for prospective clients.